Les maladies cardio-vasculaires sont la première cause de mortalité dans le monde, des pathologies évitables lorsqu’elles sont décelées précocement. Le laboratoire de Paolo Samorì a développé une nouvelle génération de capteurs ultra-sensibles, pouvant notamment servir à collecter des données de santé. Ce type de dispositif permet d’alerter dès les premiers signes imperceptibles du développement d’une maladie cardio-vasculaire. Ce capteur nouvelle génération, couplé à la puissance d’analyse de l’Intelligence Artificelle, constitue un outil de prévention et de diagnostic prometteur.

This article examines the epidemiology and characteristics of Candida auris, an emerging multidrug-resistant fungal pathogen, across the Middle East and North Africa. The research systematically reviews reported cases throughout the Gulf Region, including Saudi Arabia, Qatar, the United Arab Emirates, Kuwait, Oman, and Bahrain, as well as the Eastern Mediterranean Region and North African countries such as Egypt, Algeria, and Sudan. The study analyzes case distribution patterns across these geographic areas and compares pre-COVID and post-COVID emergence trends, revealing significant temporal shifts in disease prevalence. Notably, the research identifies predominant clade distributions specific to different regions, providing crucial insight into the pathogen's genetic diversity and geographic spread. Additionally, the analysis addresses antifungal resistance profiles, a critical concern given Candida auris's notorious resistance to multiple treatment options. This comprehensive regional assessment matters significantly for public health planning and infection control strategies, as Candida auris poses substantial clinical challenges in healthcare settings throughout the Middle East and North Africa, particularly in resource-constrained environments where surveillance and containment remain difficult.

Urinary tract infections represent a significant global health burden, affecting millions annually with rising antimicrobial resistance complicating treatment outcomes. This comprehensive review examines the clinical microbiological diagnostic workflow essential for accurate UTI management and targeted therapy. The article outlines the complete diagnostic pathway, beginning with specimen collection and traditional Gram staining, progressing through quantitative urine culture to advanced identification techniques including matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), biochemical assays, and multilocus sequence typing. The review also addresses antimicrobial susceptibility testing methods ranging from broth microdilution to automated systems and diffusion tests, alongside emerging molecular diagnostics such as multiplex polymerase chain reaction and next-generation sequencing for rapid resistance detection. The integration of conventional phenotypic testing with modern molecular diagnostics enables timely transition from empirical to targeted antimicrobial therapy, supporting antimicrobial stewardship initiatives and reducing unnecessary broad-spectrum antibiotic exposure. This systematic diagnostic approach proves increasingly critical as multidrug-resistant pathogens proliferate, ultimately advancing precision medicine implementation in UTI management while enhancing clinical outcomes.

Molecular point-of-care testing (POCT) offers promise for rapid infectious-disease diagnosis to guide isolation, referral, and treatment decisions. This critical review examines POCT as an integrated biosensing system, integrating CRISPR-Cas recognition, isothermal amplification, microfluidic sample handling, nanomaterial-assisted preparation, and smartphone readout with considerations for contamination control, matrix tolerance, multiplexing, calibration, and reagent stability. The authors propose a five-domain framework evaluating mechanistic feasibility, analytical characterization, clinical accuracy, usability and operations, and clinical utility and implementation, applied to respiratory infections, sexually transmitted infections, and antimicrobial-resistance testing. While clinically evaluated cartridge systems demonstrate stronger diagnostic evidence than emerging prototypes, randomized trials show rapid pathogen identification does not necessarily reduce antibiotic prescribing, highlighting the distinction between genotypic resistance detection and phenotypic susceptibility testing. The One Health framework examines transferable engineering constraints in foodborne-pathogen detection, water surveillance, and antimicrobial-exposure monitoring. Key implementation priorities include internal process controls, transparent invalid-result reporting, prospective real-world evaluation, reproducible manufacturing, affordability, secure connectivity, and explicit linkage between test results and appropriate clinical actions.

Candida auris represents a significant global public health threat requiring rapid and accurate diagnostic identification and antifungal susceptibility testing. Recent comprehensive reviews and clinical studies address the critical diagnostic challenges posed by this emerging pathogenic yeast. Multiple identification methodologies have been evaluated, including MALDI-ToF mass spectrometry, which provides reliable species profiling capabilities. The Simplexa C. auris Direct assay demonstrates multicenter performance validation for detecting colonization through bilateral axilla and groin swabs, supporting efficient screening protocols. Current antifungal susceptibility testing against amphotericin B, echinocandins, and flucytosine now follows newly established European Committee for Antimicrobial Susceptibility Testing (EUCAST) breakpoints, enabling standardized interpretation of minimum inhibitory concentrations. These diagnostic advances are essential for clinical laboratories implementing effective surveillance and treatment strategies. As Candida auris continues spreading globally with documented antifungal resistance patterns, robust identification and susceptibility testing frameworks enable healthcare systems to promptly detect infections, guide therapeutic decisions, and implement appropriate infection control measures to mitigate transmission risks and improve patient outcomes.

Researchers have developed a programmable multi-dimensional microfluidic system that significantly advances decentralized diagnostics, as reported in Nature Communications. This innovative platform, created by a team of scientists including Tao Xu, Ying Zhang, and colleagues, reimagines how diagnostic testing can be conducted outside traditional laboratory settings. The microfluidic technology enables simultaneous multi-parameter analysis from minimal sample volumes, enhancing diagnostic accuracy and speed while reducing costs associated with centralized testing facilities. By leveraging programmable microfluidics—a technique that allows precise control of fluid behavior at microscale—the system can perform diverse diagnostic functions on a single integrated device. This breakthrough is particularly significant for point-of-care testing applications, enabling healthcare providers to deliver rapid, accurate diagnostics in remote or resource-limited settings. The approach addresses critical gaps in accessible healthcare by democratizing diagnostic capabilities, potentially transforming disease detection and management protocols in global health contexts.

Researchers from Yancheng Clinical College evaluated a comprehensive antimicrobial stewardship intervention targeting ICU patients with bloodstream infections. Between March 2022 and June 2023, the laboratory implemented an optimized workflow incorporating satellite blood culture incubation in the emergency department, upgraded culture bottles, rapid MALDI-TOF MS identification, automated rapid antimicrobial susceptibility testing (AST) reporting, and dual AST cards for Gram-negative bacteria. Comparing 153 post-optimization patients to 107 pre-optimization controls, results demonstrated that rapid AST reporting was 19.6 hours faster than conventional reporting. Total antibiotic duration decreased by 1.5 days, with significant reductions in broad-spectrum antibiotic usage, including meropenem and tigecycline. Hospital length of stay was reduced by five days. These findings underscore the substantial clinical and economic benefits of expedited diagnostic workflows in managing bloodstream infections, enabling faster pathogen identification and appropriate targeted antimicrobial therapy while reducing unnecessary broad-spectrum antibiotic exposure and healthcare costs.

UR Next Lab and Services Solutions, LLC addresses the clinical challenge of balancing diagnostic speed with accuracy in infectious disease testing. The company offers two complementary approaches: FDA-cleared, CLIA-waived Point-of-Care rapid diagnostics delivering results in ten to fifteen minutes, and Molecular RT-PCR/NAAT amplification panels for definitive diagnosis. Point-of-Care antigen tests employ monoclonal antibodies on nitrocellulose membranes or fluorescence cartridges to detect viral proteins or bacterial antigens from nasal or throat swabs, providing quick clinical guidance when symptoms are evident. Conversely, Reverse Transcription Polymerase Chain Reaction and Nucleic Acid Amplification Testing represent the gold standard for molecular diagnosis, directly amplifying pathogenic genetic material through thermal cycling. This approach exponentially multiplies viral RNA or DNA sequences—potentially generating over one billion copies from a single molecule within thirty-five to forty cycles—enabling detection of as few as one hundred to five hundred viral copies per milliliter. This superior sensitivity allows molecular testing to identify infections days before rapid tests become positive and maintains sensitivity throughout recovery, making it invaluable when early-stage symptoms are ambiguous or rapid tests yield false negatives despite clinical presentation.

Molecular diagnostics is undergoing a fundamental transformation from a specialized niche to core laboratory infrastructure, marking a shift from crisis-driven pandemic demand to sustainable, technology-anchored growth. The Indian molecular diagnostics market, valued at approximately ₹9,400 crore (USD 1 billion) in 2025, exemplifies this evolution. Characterized as reagent-heavy and PCR-anchored, it remains substantially import-dependent while expanding into genomics and oncology applications across smaller cities. The segment is transitioning from double-digit pandemic-era growth rates to projected compound annual growth of six to eight percent through the decade, reflecting a stabilization around infectious disease, oncology, and genetic testing rather than single-pathogen spikes. This structural shift is reshaping procurement economics, technology choices, and industry consolidation patterns. For diagnostic chains, hospital laboratories, and equipment suppliers, the strategic imperative has shifted from capacity expansion to optimizing workflows, capital allocation, and integrated reagent-driven infrastructure. The market's emphasis on reagents and consumables over analyzers underscores this transition, positioning reagent supply chains and workflow integration as competitive differentiators in the evolving molecular diagnostics landscape.

Bacterial antimicrobial resistance caused an estimated 1.27 million deaths in 2019, yet antimicrobial susceptibility testing (AST)—essential for guiding targeted therapy and stewardship—remains inaccessible in low-resource settings. Researchers from Hormuud University in Somalia conducted a narrative review of literature published between 2019 and 2026, searching PubMed, Scopus, and Google Scholar for studies addressing economic barriers to AST implementation in low- and middle-income countries. The analysis identified three interconnected levels of economic obstruction: patient-level barriers including out-of-pocket costs and transportation; laboratory-level constraints such as infrastructure deficits, reagent shortages, and insufficient workforce; and health-system-level underinvestment coupled with donor dependency. These barriers perpetuate broad-spectrum empirical prescribing, amplifying selection pressure and driving emergence of resistant organisms including methicillin-resistant Staphylococcus aureus, extended-spectrum β-lactamase-producing Enterobacterales, and carbapenem-resistant pathogens. Consequences extend beyond treatment failure to catastrophic household expenditures and threats to universal health coverage. The authors recommend subsidized diagnostics, insurance coverage for microbiology services, tiered laboratory strengthening, and integrated diagnostic and antimicrobial stewardship programs as essential responses to scale AST accessibility and combat resistance.

AmplexDiagnostics and Scope Biosciences have announced eazySNP, an innovative molecular diagnostic technology that combines LAMP and CRISPR methodologies to enable rapid and highly specific detection of genetic variants. The collaboration represents a significant advancement in molecular SNP diagnostics. The first CE-IVD certified product, eazySNP C. auris FKS1 S639, targets Candidozyma auris, a multidrug-resistant yeast pathogen of major clinical concern. This assay rapidly identifies echinocandin-resistance mutations in the FKS1 gene—critical for treatment planning since echinocandins are the first-line therapy for C. auris infections. Performed directly from yeast colonies using the eazyMini platform, results are delivered within 45 minutes, providing laboratories with the first rapid molecular solution for detecting this clinically important resistance marker. For Scope Biosciences, this launch marks a strategic expansion from plant health diagnostics into human molecular diagnostics, demonstrating the commercial viability of their CRISPR technology platform.

“La nouvelle Steve Jobs”. En septembre 2015, le magazine Inc. consacre sa couverture et un portrait dithyrambique à Elizabeth Holmes. Personne ne le sait encore, mais ce sont les derniers instants de gloire pour la fondatrice de Theranos, devenue alors, à 31 ans, la plus jeune milliardaire non héritière au monde. Le 16 octobre, le château de cartes qu’elle a bâti pendant onze ans commence à s’effondrer, à la suite de la publication d’une enquête dévastatrice du Wall Street Journal. Malgré les dénégations, ces révélations emporteront tout sur leur passage, précipitant la chute de l’entrepreneuse et la conduisant jusqu’en prison.

Advanced diagnostics determine over 70% of clinical decisions yet receive only 2% of global healthcare spending, creating a critical gap in health equity—particularly in Asia-Pacific. The region faces disproportionate disease burdens, accounting for 62.6% of global liver disease deaths, 60% of tuberculosis cases, and nearly half of global breast cancer diagnoses, compounded by rapid population ageing projected to increase significantly by 2050. This diagnostic underinvestment has serious consequences: missed or imprecise diagnoses cannot always be corrected later, even with advanced therapies, affecting critical applications like immunosuppressive drug dosing post-transplant. Technological innovations, particularly automated mass spectrometry, are transforming access to precision diagnostics in routine clinical settings across Asia-Pacific. By enabling high-specificity molecular detection without requiring specialized laboratory facilities, these scalable technologies make precision care accessible where it's needed most. Expanding diagnostic capabilities in the region is essential to manage rising chronic disease burdens and address the current undervaluation of diagnostics by both medical professionals and policymakers globally.

The United States recorded 6,304 new clinical cases of Candida auris in 2024, continuing an upward trajectory since the fungus's first U.S. detection in 2016, though the rate of increase has recently slowed. C. auris cases are identified through clinical samples from invasive sites like blood or cerebrospinal fluid, or non-invasive sites such as urine and wounds, with screening cases detected through colonization swabs. While transmission persists in certain geographic areas and has expanded into new regions, recommended infection prevention and control practices have successfully contained outbreaks in some locations when implemented early. The CDC, collaborating with state and local health departments, diagnostic laboratories, and healthcare facilities, tracks cases reported through standardized Council of State and Territorial Epidemiologists definitions and provides support via its Antimicrobial Resistance Lab Network. Proactive case detection, patient screening, and rigorous adherence to infection control protocols remain critical for preventing healthcare facility outbreaks and limiting this emerging threat's spread.

Researchers have developed a rapid diagnostic approach for identifying pathogenic microorganisms directly from positive blood cultures and simultaneously determining their antimicrobial susceptibility profiles. Published in PLOS One by Xu and colleagues, this study addresses a critical clinical challenge in sepsis management, where timely identification of bloodstream pathogens and their resistance patterns is essential for appropriate antibiotic selection. Traditional methods require lengthy culture periods, delaying treatment decisions and potentially compromising patient outcomes. The research presents an expedited testing methodology that significantly reduces the time-to-result for both pathogen identification and susceptibility testing from positive blood culture samples. By enabling faster diagnosis and resistance profiling, this approach allows clinicians to implement targeted antimicrobial therapy more rapidly, potentially improving treatment efficacy and reducing inappropriate antibiotic use. The innovation holds substantial value for intensive care settings and clinical microbiology laboratories, where rapid turnaround times directly impact patient prognosis in life-threatening bloodstream infections.

Point-of-care CRISPR-based diagnostics represent a transformative approach to molecular testing that combines laboratory precision with rapid, decentralized deployment. While traditional CRISPR platforms utilize intact guide RNA and single Cas effector proteins, they frequently suffer from background signal leakage, off-target activation, and complex sample preparation. Bioengineers have developed split molecular systems that address these limitations by dividing essential CRISPR components into inactive fragments that remain non-functional until a target sequence appears in the sample. Upon target hybridization, these fragments spontaneously assemble into an active Cas complex that initiates collateral cleavage of reporter molecules. This conditional mechanism dramatically suppresses baseline noise while enabling extraordinary diagnostic fidelity. The split crRNA architecture divides the guide RNA into multiple inactive fragments that cannot independently activate Cas endonucleases. When a specific complementary target sequence is introduced, rapid hybridization triggers reassembly of a complete, catalytically functional guide RNA. This dual-recognition system suppresses spurious enzymatic activation and prevents accidental off-target cleavage from mismatched sequences. By fine-tuning thermodynamic hybridization properties of each fragment, assay designers achieve single-base discrimination, enabling reliable differentiation of viral variants and drug-resistant bacterial strains. This split system approach establishes a dependable foundation for high-precision molecular detection in primary care settings without requiring expensive laboratory infrastructure.

Molecular public health represents an emerging paradigm that integrates molecular epidemiology with public health practice to enhance infectious disease prevention and surveillance. This comprehensive review examines the conceptual framework and technological infrastructure underpinning this integrated approach. Key components include bioinformatics and data integration systems that serve as interpretive engines for molecular datasets, alongside molecular detection and quantification technologies that enable precise pathogen identification. The review emphasizes next-generation sequencing for pathogen genomic surveillance, genomic epidemiology and phylodynamics for tracking disease transmission, and metagenomics for pathogen-agnostic surveillance capabilities. Novel applications include wastewater and environmental surveillance for early disease detection, One Health molecular surveillance coordinating human-animal-environmental monitoring, and molecular approaches to antimicrobial resistance tracking. Advanced techniques such as multi-omics analysis and host-response surveillance provide deeper biological insights, while artificial intelligence and computational public health optimize data interpretation and predictive modeling. Together, these technologies create a sophisticated surveillance ecosystem that enables real-time pathogen monitoring, rapid outbreak detection, and evidence-based public health interventions for emerging and re-emerging infectious diseases.

Matrix-Assisted Laser Desorption Ionization Time-Of-Flight (MALDI-TOF) mass spectrometry has emerged as a transformative technology for rapid microbial identification across clinical, environmental, and industrial applications. Recent research demonstrates the integration of MALDI-TOF with artificial intelligence significantly enhances bacterial and viral pathogen classification accuracy and speed, addressing critical needs in clinical diagnostics and biodefense. Notable developments include IDBac, an open-access web platform enabling bacteria identification and relationship analysis using MALDI-TOF mass spectrometry, published in Nature Communications. Comparative studies reveal performance differences between systems, including the Bruker Microflex LT Biotyper and the newer Zybio EXS2600 Ex-Accuspec, tested on 1,130 milk bacterial isolates. The technology demonstrates particular value in detecting antibiotic resistance in Burkholderia pseudomallei and identifying microbial contamination in diesel fuels. These advances matter significantly because rapid, accurate pathogen identification enables faster clinical interventions, supports public health surveillance for antibiotic-resistant organisms, and protects fuel system integrity and operational safety across diverse sectors.

Horizon Europe Cluster 6 is launching funding opportunities for 2026-2027 addressing critical challenges in food security, biodiversity conservation, land management, and bioeconomy development. The call calendar opens between January and August 2026, with subsequent openings in February and April 2027, featuring deadlines spanning April through September 2026 and extending into May 2027. A microfluidic technology specialist has analyzed the cluster's work programme to identify calls with significant relevance to microfluidic applications. Key opportunities with highest microfluidic relevance include commercializing food systems microbiome solutions, integrating holistic microbiome research for sustainable food systems, assessing groundwater ecosystem functions, decontaminating and bioremediation of aquatic pollution, advancing European bio-based innovation through biotechnology and biomanufacturing, developing microbiome applications for livestock sustainability, and implementing advanced solutions for controlled environment agriculture. The analysis ranks microfluidic relevance from fifty to one hundred percent across eligible topics. This strategic assessment enables SMEs and research organizations to identify optimal funding opportunities aligned with microfluidic engineering capabilities and innovation potential within European agricultural and environmental priorities.

The COVID-19 pandemic exposed critical diagnostic testing gaps, with laboratories overwhelmed by high sample volumes, delayed results, and compromised disease control. While existing point-of-care testing devices lack sensitivity and molecular tests like PCR demand complex infrastructure and trained personnel, contamination risks further limit decentralized testing. This patent introduces an innovative, fully integrated microfluidic device for nucleic acid molecular point-of-care testing that operates on a "sample-in, result-out" workflow without requiring laboratory settings or specialized training. The disposable device comprises three components: a sample tube with buffer, a microfluidic reaction tube pre-loaded with dried amplification reagents, and a readout cartridge. Its closed-system design prevents contamination through sealed connections, while capillary-driven fluidics and thermally activated valves control liquid transfer. A puncture mechanism releases amplified products onto a lateral flow assay strip for colorimetric detection. By eliminating manual steps like pipetting and centrifugation and employing isothermal amplification such as LAMP, the device enables rapid, equipment-free nucleic acid detection. This innovation addresses the urgent need for portable, user-friendly, contamination-proof molecular diagnostics accessible in non-laboratory environments.